CN106459017B - 作为可溶性鸟苷酸环化酶活化剂的杂环羧酸 - Google Patents

作为可溶性鸟苷酸环化酶活化剂的杂环羧酸 Download PDF

Info

Publication number
CN106459017B
CN106459017B CN201580033515.4A CN201580033515A CN106459017B CN 106459017 B CN106459017 B CN 106459017B CN 201580033515 A CN201580033515 A CN 201580033515A CN 106459017 B CN106459017 B CN 106459017B
Authority
CN
China
Prior art keywords
mmol
mixture
reduced pressure
under reduced
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580033515.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106459017A (zh
Inventor
J·B·布伦尼曼
J·D·吉恩
C·R·萨尔科
J·韦斯特布鲁克
章忠华
M·于
T·D·霍普金斯
M·D·洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53783363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106459017(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN106459017A publication Critical patent/CN106459017A/zh
Application granted granted Critical
Publication of CN106459017B publication Critical patent/CN106459017B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
CN201580033515.4A 2014-07-22 2015-07-21 作为可溶性鸟苷酸环化酶活化剂的杂环羧酸 Active CN106459017B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462027376P 2014-07-22 2014-07-22
US62/027,376 2014-07-22
PCT/US2015/041245 WO2016014463A1 (en) 2014-07-22 2015-07-21 Heterocyclic carboxylic acids as activators of soluble guanylate cyclase

Publications (2)

Publication Number Publication Date
CN106459017A CN106459017A (zh) 2017-02-22
CN106459017B true CN106459017B (zh) 2020-07-17

Family

ID=53783363

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580033515.4A Active CN106459017B (zh) 2014-07-22 2015-07-21 作为可溶性鸟苷酸环化酶活化剂的杂环羧酸

Country Status (26)

Country Link
US (1) US9353090B2 (cg-RX-API-DMAC7.html)
EP (1) EP3172202B1 (cg-RX-API-DMAC7.html)
JP (1) JP6602840B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170035993A (cg-RX-API-DMAC7.html)
CN (1) CN106459017B (cg-RX-API-DMAC7.html)
AP (1) AP2016009615A0 (cg-RX-API-DMAC7.html)
AR (1) AR101265A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015292833B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017000943A2 (cg-RX-API-DMAC7.html)
CA (1) CA2955937A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017000071A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017000438A2 (cg-RX-API-DMAC7.html)
DK (1) DK3172202T3 (cg-RX-API-DMAC7.html)
EA (1) EA032972B1 (cg-RX-API-DMAC7.html)
ES (1) ES2784477T3 (cg-RX-API-DMAC7.html)
HU (1) HUE049231T2 (cg-RX-API-DMAC7.html)
IL (1) IL249587A0 (cg-RX-API-DMAC7.html)
MX (1) MX378717B (cg-RX-API-DMAC7.html)
PE (1) PE20170249A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500111A1 (cg-RX-API-DMAC7.html)
PL (1) PL3172202T3 (cg-RX-API-DMAC7.html)
PT (1) PT3172202T (cg-RX-API-DMAC7.html)
SG (2) SG11201700507XA (cg-RX-API-DMAC7.html)
TW (1) TWI711615B (cg-RX-API-DMAC7.html)
UY (1) UY36226A (cg-RX-API-DMAC7.html)
WO (1) WO2016014463A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180104123A (ko) 2016-02-01 2018-09-19 아이언우드 파마슈티컬스, 인코포레이티드 비알콜성 지방간염 (NASH)의 치료를 위한 sGC 자극제의 용도
US10570074B2 (en) 2016-09-14 2020-02-25 Genomatica, Inc. 1,3-fatty diol compounds and derivatives thereof
CN109890379A (zh) 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
CN106495999B (zh) * 2016-10-18 2019-08-16 亳州学院 一种芳香醛及其合成方法
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
TW201920197A (zh) 2017-07-14 2019-06-01 英商葛蘭素史克智慧財產發展有限公司 化合物
EP3668834B1 (en) * 2017-08-17 2024-10-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
WO2019207517A1 (en) * 2018-04-27 2019-10-31 Hetero Labs Limited Process for preparation of ((3r,11br)-1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d 3)-3-(2-methylpropyl)-2h-benzo[a]quinolizin-2-one
CA3098475A1 (en) 2018-04-30 2019-11-07 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
EA202092680A1 (ru) 2018-05-15 2021-04-13 Байер Акциенгезельшафт 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
EA202191554A1 (ru) 2018-12-03 2021-09-02 Фмк Корпорейшн Способ получения n-фенилпиразол-1-карбоксамидов
EP3911675A1 (en) 2019-01-17 2021-11-24 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
FI4182297T3 (fi) 2020-07-16 2025-12-05 Acuitas Therapeutics Inc Kationisia lipidejä käytettäväksi lipidinanohiukkasissa
CN114957087A (zh) * 2022-04-13 2022-08-30 湖南复瑞生物医药技术有限责任公司 一种帕罗韦德中间体制备方法
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122340A1 (en) * 2011-03-10 2012-09-13 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
WO2013025425A1 (en) * 2011-08-12 2013-02-21 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
WO2014039434A1 (en) * 2012-09-07 2014-03-13 Boehringer Ingelheim International Gmbh Alkoxy pyrazoles as soluble guanylate cyclase activators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026712A2 (en) 2000-09-29 2002-04-04 Millennium Pharmaceuticals, Inc. Quaternary amines and related inhibitors of factor xa
EP1906957A1 (en) 2005-07-18 2008-04-09 Bayer HealthCare AG Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders
US20080045560A1 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
CA2686906A1 (en) 2007-05-12 2008-11-20 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators, sgc activators and combinations for the treatment of urological disorders
JP5298129B2 (ja) 2007-09-06 2013-09-25 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化因子
CA2706241C (en) 2007-10-05 2015-12-22 Sanofi-Aventis Deutschland Gmbh Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
PE20091258A1 (es) 2007-12-03 2009-09-12 Smithkline Beecham Corp Derivados de piridina como activadores de la guanilato ciclasa soluble
CA2720343A1 (en) 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
WO2010015652A2 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Thiazole compounds as activators of soluble guanylate cyclase
WO2010015653A1 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
ES2493718T3 (es) 2009-01-17 2014-09-12 Bayer Intellectual Property Gmbh Estimuladores y activadores de sGC en combinación con inhibidores de PDE5 para el tratamiento de la disfunción eréctil
WO2010099054A2 (en) 2009-02-26 2010-09-02 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2011095553A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
PT2531187E (pt) 2010-02-05 2015-10-20 Adverio Pharma Gmbh Estimuladores de sgc ou ativadores de sgc sozinhos e em combinação com inibidores de pde5 para o tratamento de fibrose cística (fc)
PL2576548T3 (pl) 2010-05-26 2015-11-30 Adverio Pharma Gmbh Zastosowanie stymulatorów sGC, aktywatorów sGC, pojedynczo i w kombinacjach z inhibitorami PDE5, w leczeniu twardziny układowej (SSc)
WO2011161099A1 (de) 2010-06-25 2011-12-29 Bayer Pharma Aktiengesellschaft Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2594270A3 (en) 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
WO2015095515A1 (en) 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122340A1 (en) * 2011-03-10 2012-09-13 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
WO2013025425A1 (en) * 2011-08-12 2013-02-21 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
WO2014039434A1 (en) * 2012-09-07 2014-03-13 Boehringer Ingelheim International Gmbh Alkoxy pyrazoles as soluble guanylate cyclase activators

Also Published As

Publication number Publication date
SG11201700507XA (en) 2017-02-27
UY36226A (es) 2016-01-29
DK3172202T3 (da) 2020-04-27
EA032972B1 (ru) 2019-08-30
KR20170035993A (ko) 2017-03-31
CN106459017A (zh) 2017-02-22
CL2017000071A1 (es) 2017-06-30
WO2016014463A1 (en) 2016-01-28
IL249587A0 (en) 2017-02-28
MX378717B (es) 2025-03-10
CA2955937A1 (en) 2016-01-28
MX2017000926A (es) 2017-05-04
JP6602840B2 (ja) 2019-11-06
EA201790246A1 (ru) 2017-07-31
JP2017521457A (ja) 2017-08-03
TW201617340A (zh) 2016-05-16
EP3172202B1 (en) 2020-01-29
TWI711615B (zh) 2020-12-01
HUE049231T2 (hu) 2020-09-28
US20160024059A1 (en) 2016-01-28
CO2017000438A2 (es) 2017-08-31
AU2015292833B2 (en) 2019-11-28
PL3172202T3 (pl) 2020-07-13
US9353090B2 (en) 2016-05-31
BR112017000943A2 (pt) 2017-11-14
AU2015292833A1 (en) 2016-12-22
ES2784477T3 (es) 2020-09-28
AP2016009615A0 (en) 2016-12-31
EP3172202A1 (en) 2017-05-31
AR101265A1 (es) 2016-12-07
SG10201806565SA (en) 2018-08-30
PE20170249A1 (es) 2017-04-05
PH12017500111A1 (en) 2017-05-29
PT3172202T (pt) 2020-05-06

Similar Documents

Publication Publication Date Title
CN106459017B (zh) 作为可溶性鸟苷酸环化酶活化剂的杂环羧酸
CN104619695B (zh) 作为可溶性鸟苷酸环化酶活化剂的烷氧吡唑
CN104011052B (zh) 化合物
CN105683188B (zh) 作为fgfr4抑制剂的稠环二环吡啶基衍生物
CN108697710B (zh) 作为nik抑制剂的新颖的经取代的氰基吲哚啉衍生物
CN106029076A (zh) 作为bet溴域抑制剂的苯并哌嗪组合物
CN104011025A (zh) 作为fgfr激酶调节剂的喹啉
CN108473464A (zh) 具有抗癌活性的mdm2-p53相互作用的异吲哚啉酮抑制剂
CN103119043A (zh) 稠合的杂环化合物及其用途
TW201625639A (zh) 巨環ｌｒｒｋ２激酶抑制劑
CN106661032A (zh) 治疗或预防糖尿病、肥胖症和炎性肠病的1,3‑取代的2‑氨基吲哚衍生物及类似物
CN115232108A (zh) Sos1降解剂及其制备方法和应用
CN104926801A (zh) 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用
CN108727340A (zh) 氟取代的吲唑类化合物及其用途
CN114981270B (zh) Mll1抑制剂和抗癌剂
TW202132288A (zh) Ｔｒｅｋ（ｔｗｉｋ相關的ｋ＋通道）通道功能的調節劑
WO2025209520A1 (zh) 一种化合物、包含其的药物组合物及其用途
WO2025056065A1 (zh) 一种趋化因子受体拮抗剂、药物组合物和应用
CN119032079A (zh) 新颖的取代的氟化乙烯基-n-丙基-吡咯烷化合物、用于其制备的方法及其治疗用途
HK1210164B (en) Alkoxy pyrazoles as soluble guanylate cyclase activators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant